Biogen, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Phil Nadeau from TD Cowen maintained a Buy rating on the stock and has a $175.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Phil Nadeau’s rating is based on Biogen’s strong third-quarter performance, which exceeded revenue and earnings per share expectations. Despite a reduction in 2025 earnings guidance due to business development charges, revenue guidance has been revised upwards, indicating resilience in Biogen’s core franchises. The company’s cash flow potential appears undervalued, and while investors seek clearer revenue growth, the current valuation presents an attractive opportunity.
Leqembi’s sales have shown a steady increase, particularly in the U.S., and Biogen remains optimistic about its long-term growth prospects. The expansion of Skyclarys into over 40 countries further supports Biogen’s growth trajectory, with geographic expansion being a significant driver. These factors contribute to Phil Nadeau’s confidence in maintaining a Buy rating for Biogen, supported by a discounted cash flow-based price target of $175.
Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Kura Oncology, and Biogen. According to TipRanks, Nadeau has an average return of 6.9% and a 46.36% success rate on recommended stocks.